Quince Therapeutics completed the sale of its Italian subsidiary, Quince SpA, along with specific intellectual property related to its AIDE technology for Ataxia-Telangiectasia and associated equipment, to Ayma Therapeutics for $450,000 in cash. Concurrently, President Charles Ryan departed effective September 8, 2026, receiving a lump-sum severance payment of approximately $1.01 million under his executive agreement. The company operates in the biotechnology industry.

Quince Therapeutics received a notice from Nasdaq on August 31, 2026, for failing to meet the $10 million minimum stockholders' equity requirement, citing a deficit of ($35.3 million) as of June 30, 2026. The company has until October 15, 2026, to submit a compliance plan and may receive an extension until February 27, 2027. Quince is evaluating alternatives to regain compliance and references a pending listing application that could result in a name change to IRulya Therapeutics Inc. and a transfer to the Nasdaq Capital Market under the symbol IRLA. The company operates in the biotechnology industry.

Quince Therapeutics announced that President Charles Ryan will depart the company on September 8, 2026. Mr. Ryan is eligible for severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023. The filing does not disclose specific monetary amounts or identify a successor officer at this time. Quince Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases.

Quince Therapeutics, Inc. announced plans to hold a special meeting of stockholders to approve the issuance of common stock upon conversion of its Series C Non-Voting Convertible Preferred Stock and exercise of related warrants. This issuance is required because it will represent more than 20% of outstanding shares and may trigger a change of control under Nasdaq Listing Rules. The company also filed unaudited pro forma financial information as of June 30, 2026, reflecting the conversion of approximately 211,302 preferred shares into roughly 10.99 million common shares. This follows the May 2026 acquisition of Orphai Therapeutics and a concurrent $115 million PIPE financing involving Series C Preferred Stock issued at $797.50 per share. Quince Therapeutics operates in the biotechnology industry, focusing on developing treatments for rare diseases.

Quince Therapeutics completed the acquisition of Orphai Therapeutics on May 18, 2026, adding LAM-001, an inhaled rapamycin formulation for pulmonary diseases, to its pipeline. Concurrently, the company closed a private placement raising $115 million in gross proceeds and $103.6 million net, with potential additional warrants worth up to $83 million. Cash and cash equivalents totaled $116 million as of June 30, 2026, sufficient to fund operations through the end of 2028. For the quarter ended June 30, 2026, Quince reported a net loss of $75.5 million ($12.31 per share), driven by $59 million in acquired in-process R&D and $9.1 million in non-cash stock-based compensation related to the acquisition. The company initiated a Phase 2b trial for LAM-001 in PH-ILD, with top-line data expected in Q1 2028, while BOS data is anticipated in Q1 2027. Quince Therapeutics operates as a clinical-stage biopharmaceutical company developing disease-modifying therapies for serious underserved pulmonary diseases.

Quince Therapeutics announced conditional resignations of CEO and CMO Dirk Thye and COO Brendan Hannah, effective two business days after the September 25, 2026 Special Meeting. These departures are contingent on stockholder approval of proposals to issue shares upon conversion of Series C Preferred Stock and exercise of warrants related to the Orphai acquisition and concurrent PIPE financing, which would represent over 20% of outstanding common stock under Nasdaq rules. The Board also approved conditional appointments of Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO, all effective at the same time. Additionally, the Board reduced its size from five to four directors immediately upon Thye's resignation. Quince Therapeutics operates in the biotechnology industry, focusing on developing therapeutic treatments.